A halal biosimilar anemia treatment drug to be exported to major Islamic markets from Korea

halalmedia | Posted 2020/03/28 [15:50]

A halal biosimilar anemia treatment drug to be exported to major Islamic markets from Korea

halalmedia | 입력 : 2020/03/28 [15:50]

Panzen, a South Korean biopharmaceutical company, announced on the 20th of February that it has obtained a Halal certification from the Korea Islam(KMF) for an anemia treatment biosimilar, 'Panpotin'. 

 

▲ Panpotin     © halalmedia


Panpotin is an epoetin alpha-based anemia treatment and is the first biosimilar product developed by Panzen. The halal certification is the first case of biopharmaceuticals developed in South Korea.

 

▲ Panzen logo     © halalmedia

 

An official from Panzen said, "As the sales volume of Panpotin continues to increase at home and abroad, we have acquired Halal certification as part of the market diversification strategy." He added, "The acquisition of  halal certification is more meaningful because it is very difficult to obtain Halal certification as biopharmaceuticals are exposed to serum and other animal-derived ingredients in the manufacturing process."

 

The sales of Panpotin are increasing in overseas markets with increased product awareness. In the Malaysian market, sales began in March last year with the product name 'ERYSAA', and the market share continues to increase. The company expects that the acquisition of this Halal certification will enable rapid product registration in major export markets in Saudi Arabia and Southeast Asian Muslim countries.

 

Recently, Islamic countries are expected to demand even more expensive halal-certified drugs as their income levels rise along with economic growth. The company plans to accelerate marketing of Islamic countries in the future, starting with the acquisition of Halal certification.

 
K Halal News popular articles